After combing the latest data of private placement network, the reporter of Securities Daily found that in the first three quarters of this year, 15468 equity private equity products with data statistics in the whole market achieved an average yield of 19.7%, of which 86% of the products obtained positive returns. In terms of strategy, the performance of macro strategy, stock bull, management futures and composite strategy private placement products ranked top.
The reporter found that up to now, there are 270 macro strategic private placement products with data statistics in the whole market, with the average yield of 24.21% in the first three quarters of this year, ranking first among the eight private placement strategies. Among them, 86.67% of these products achieved positive income.
In the second place is the long strategy private placement products. There are 9137 such products with an average return of 23.58%. Among them, 85.61% of these products have obtained positive income. In the third place, there are 1052 private placement products of management futures strategy in the whole market, with an average yield of 21.84% in the first three quarters. More than 80% of such products also recorded positive income. Compound strategy private placement products ranked fourth with 1376 in the whole market, with an average return of 18.96% over the same period. Among them, 85.47% of these products have obtained positive income.
Private placement is generally optimistic
Investment opportunities in the fourth quarter
In an interview with reporters, Hu Po, the future star fund manager of private placement paipaipai.com, said that the overall fluctuation of equity market this year is big and the trend is obvious. The A-share market has stepped out of a structural bull market, with major indexes rising by more than 10%. Among the leading sectors of science and technology, medicine and consumption, high-quality stocks have achieved double returns. As a result, the overall performance of stock strategy private placement products this year is good. In particular, private equity products that prefer science and technology, medicine and consumption have achieved a very high rate of return.
Hu said that the first half of this year affected by the epidemic, different sectors of the sector had a round of sharp decline. After the market sentiment is fully digested, with the cooperation of sufficient liquidity, a shares have a strong rebound. Because of the large fluctuation of the market before and after, the relative value, event driven and futures strategy private equity products have good market performance. In addition, the macro strategy and composite strategy private equity products also benefit from the good performance of the equity market, and the benefits are also considerable. The bond market has not performed well this year, mainly due to the factors of higher interest rates, which leads to poor performance of fixed income strategy private equity products.
Yin Baoqing, deputy general manager of Senrui investment, told reporters that the company insisted on the layout of investment in the pharmaceutical and biological industry this year, and the product performance in the first three quarters was good. On the one hand, it was related to the market situation, on the other hand, the medical industry showed strong resilience due to the rigid demand factors under the background of the epidemic situation. Many listed companies not only did not suffer, but benefited from it. We have grasped it The opportunity. It is expected that the structural opportunities of the A-share market in the fourth quarter are still worth looking forward to.
Zhou Wenming, the co-founder of Linze investment, said in an interview that this year is a big year for value investment. Private equity products that can select and patiently hold some high-quality leading stocks have made good profits. Private equity investment research focuses on the track, especially the consumer, pharmaceutical, technology and other industries, behind which are based on the people dividend. For the fourth quarter market, it is expected that the macro policy and economic data are likely to remain stable, and the A-share market needs a period of time to rest and regain momentum, which is exactly the best layout period.
Tong Diyi, general manager of longying fuze assets, told reporters that the outbreak of the epidemic has brought changes to the global market. On the one hand, it accelerates the technology empowerment and rapid iteration process of traditional industries; on the other hand, it provides historical development opportunities for medicine, cloud economy and other industries. In the first half of this year, based on the analysis of the impact of the epidemic and the calculation of high-frequency data, the company invested a lot in the pharmaceutical industry, and finally got a return on product performance. Looking forward to the fourth quarter, the current financial stocks are at a low valuation, and the allocation of institutions is also low. The markets concerns about bank performance have been fully digested. If we can dig out the expected difference in the third quarter report, there may be some room for valuation repair.
Source of this article: Ren Hui, editor in charge of Securities Daily_ NBJ9607